Responder Identification in Clinical Trials with Censored Data by Kehl, V. & Ulm, Kurt
Kehl, Ulm:
Responder Identification in Clinical Trials with
Censored Data
Sonderforschungsbereich 386, Paper 311 (2003)
Online unter: http://epub.ub.uni-muenchen.de/
Projektpartner
Responder Identification in Clinical Trials with Censored Data
Victoria Kehl, Kurt Ulm
Institut for Medical Statistics and Epidemiology
Technical University – Munich
Ismaningerstr. 22
81675 Munich
Germany
Tel. +49-89-4140-4348
Fax: +49-89-4140-4973
E-mail: victoria.kehl@imse.med.tu-muenchen.de
This research was supported by grant UL 94/11-1 of the German Research Community
(DFG) and by DFG’s Special Reseach Areas (SFB) 386, project B7.
Kehl & Ulm
Responder Identification in Clinical Trials with Censored Data 2
Summary
We present a newly developed technique for identification of positive and negative
responders to a new treatment which was compared to a classical treatment (or placebo)
in a randomized clinical trial. This bump-hunting-based method was developed for trials
in which the two treatment arms do not differ in survival overall. It checks in a
systematic manner if certain subgroups, described by predictive factors do show
difference in survival due to the new treatment. Several versions of the method were
discussed and compared in a simulation study. The best version of the responder
identification method employs martingale residuals to a prognostic model as response in
a stabilized through bootstrapping bump hunting procedure. On average it recognizes
90% of the time the correct positive responder group and 99% of the time the correct
negative responder group.
Keywords: responder identification, bump hunting, predictive factors
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1. Introduction
The term response up to now appears only in clinical trials, in which surrogate markers
are used to describe the effect of a treatment when that effect is other than to prevent an
event. For example in oncology, the desired effect of a treatment may be reduction of
tumor size, whereas the outcome of interest (called event) may be death. Then a
responder is a patient who experienced tumor reduction or complete remission and a
non-responder is a patient who's tumor did not change or grew. Notice, that does not
necessarily mean that responders lived longer. No definition of responder is currently
available for trials in which the effect of treatment is to prevent an event (e.g. mortality).
The classical definition of responder is altered in this research in order to fit the more
general clinical trial situation, in which the wished effect of a treatment is increasing the
event-free period of the treated patient. We define positive responders to be patients
under the new treatment, who benefit from it. Their benefit is manifested in the fact that
their survival time is longer than that of patients with the same characteristics
(predictive factors), randomized in the classical treatment group. We define negative
responders to be patients under the new treatment who are harmed by it. Their survival
time is shorter than that of a similar, described by predictive factors, group of patients
under the classical treatment. Consequently, non-responders would be patients who are
neither positive nor negative responders. Their survival time does not differ from
similar patients under the classical treatment. We are interested in identifying
responders – both positive and negative.
Let us concentrate on the following common clinical trial situation in which the ability
of a new treatment to prevent an event is tested. Patients are randomized into two
groups: one receiving the classical treatment (or placebo) and the other receiving the
new treatment. Not rarely, the outcome of such trials shows no difference in the survival
probabilities of the two treatment groups. But still, it could happen that certain
subgroups of patients show improved survival under the new treatment, while others
appear to suffer from it. Exactly this situation appeared in the European Myocardial
Infarction Amiodarone Trial (EMIAT) [1], which inspired this research. For an
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application of the proposed responder identification method on the EMIAT data set,
please refer to [2].
Suppose the survival time of a patient in the new treatment group of a clinical trial is
greater than the overall survival time. There can be three reasons for this phenomena: (i)
chance – we cannot predict or account for occurrence by chance in a model, (ii) the
patient has a prognosis better than the average, due to the specific prognostic factors
that he enjoys, (iii) the new therapy is really working. Note that prognostic factors
influence the survival time independently of treatment. One can account for prognostic
factors, provided that they have been measured, by developing a prognostic model on
the classical treatment (or placebo) group. We have chosen to use the well known Cox-
PH model for that purpose. Notice, that the factors in this model would be prognostic in
the real sense of the term only if they are found on a placebo arm. If the new treatment
is tested against a classical treatment, the factors would be "prognostic" only with
respect to the classical treatment and not in general. To avoid confusion, for the rest of
this paper we will call both factor types prognostic. 
Our goal in this research was to find a method for identifying patients with special
reactions to the new treatment (those could be positive as well as negative), which are
different from the whole patient population and cannot be explained by prognostic
factors (iii). In such cases predictive factors are responsible for the difference in
survival. Note, that a factor can have both prognostic and predictive power, if its
prognostic value is different in the two treatment groups. 
2. The Classical Approach 
Up to now, the classical and the only structured approach for responder identification in
clinical trials has been the Cox-PH model including interaction terms between the
treatment and some or all of the covariates [3]. In our setting the following version of
the Cox-PH model would be fitted on the entire data set:
  
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where i is a patient identifier, i = 1, ..., n, x  is a vector of prognostic factors, x is a
vector of coefficients of the prognostic factors, z is a vector of predictive factors (z  x
is possible), z is a vector of coefficients of the predictive factors (to avoid double
appearance, z[i] = 0 for zi  x), treat is the factor indicating treatment group (0 =
classical, 1 = new), T is the coefficient of the treatment indicator, I is a vector of
coefficients of the interaction terms.
If a certain predictive factor interaction term shows to be adding information to the
model, this should be interpreted as follows. If the coefficients in the predictive part of
the model are such, that the presence of factor zi in the model increases the hazard of
patients having that factor and taking the new treatment, we can say that zi is a
predictive factor and patients having this characteristic are negative responders of the
new treatment. Naturally, if the coefficients in the predictive part of the model lead to
reduction of the hazard in the presence of factor zi, then zi would be a predictive factor
which defines the positive responder group.
The problem with this method is, that in order for it to recognize a combination of
factors as predictive, this particular combination has to be present in the model as
interaction. Even assuming that the interaction between the factors is linear, the order of
the interaction term is unknown. If two predictive factors and factor treatment should
show interaction, one needs to consider all possible interaction terms of up to third
order, in order to give a chance of a covariate selection procedure to choose the right
combination. The number of possible interaction terms to be considered grows rapidly
as the number of factors grows. It is also known, that the power of stepwise variable
selection procedures decreases as the number of variables (variable combinations)
increases. For that reason, up to now in practice researchers have always used previous
knowledge about the factors in the study in order to do such subgroup analysis (see [4]
& [5] for examples).   
Considering the limitations of this approach, it is clear, that a new more involved
exhaustive method is needed. 
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3. The Responder Identification Method for Censored Data
We suggest the following strategy for positive and negative responder identification:
Algorithm 1
Responder Identification for Censored Data:
1. Develop a good prognostic model (e.g. Cox-PH model) on the classical
treatment arm of the data.
2. Apply the prognostic model together with its estimated coefficients and
baseline hazard to the new treatment group. 
3. Calculate residuals of the prognostic model for outlier identification in the
new treatment group. Patients who are not well predicted (outliers in the
residuals) would be candidates for responders.
4. Using the residuals as a response, develop a model on the new treatment
group which describes extreme regions of the residuals.
5. Identify the groups of patients in the classical treatment group, who
correspond to the groups with extreme residuals in the new treatment arm,
i.e. divide the classical treatment space in the same way as the new
treatment space and consider the regions which were identified as extreme
in the new treatment space. 
6. Compare the survival curves of each classical-new treatment pair of extreme
regions (log rank test). If there is a significant difference in survival, the
group with extreme positive residuals would identify negative
responders and the extreme negative residuals – positive responders.
Also, the factors involved in the description of the regions will be predictive. 
The best version of the responder identification method (as of our simulation study) is
shown schematically in the flow-chart of figure 1. 
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Figure 1. Flow diagram of the responder identification algorithm.
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4. Options in the Responder Identification Method
4.1 The Residuals
In step 3 of the responder identification method we need residuals to the Cox-PH model
which correspond to data points and are not explicitly connected to single prognostic
factors contained in the model. Such residuals would be able to identify outlying points
with poorly predicted individual outcomes by the prognostic model. Those points can be
used for predictive factor identification and, ultimately, responder identification
purposes. We suggest the use of martingale or deviance residuals despite their bad
distributional properties because of their interpretability and since no special
distributional properties are required in the responder identification method. The log-
odds and normal deviate residuals suggested by Nardi & Schemper [6] can be used as
well if interpretability in the form "expected – predicted" is of no interest.
Specifically for the Cox-PH model, the definition of martingale residuals reduces to:
),(ˆ)(ˆˆ ˆ0 iiii
Z
iii ZtetM i 


 ,
where ti is the observation time and δi is the final status for subject i [7]. Notice that
since the status can take only values of 0 or 1 and the hazard is always non-negative, the
martingale residual for the Cox-PH model takes values only in the interval (-, 1]. 
The deviance residual [8], is the signed square root of the deviance. The ln(·) function
inflates martingale residuals close to 1 and the square root contracts the large negative
values. It is zero if and only if 0ˆ iM . For the Cox-PH model, the deviance residual
simplifies to:
)]ˆln(ˆ[2)ˆsgn( iiiiii MMMd   .
For residual interpretation purposes the censoring indicator can be thought of as a
classification rule, which places patients into either the low or the high hazard group.
This results in only a few possible scenarios for the residuals:
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1. As by most other residuals, values of the martingale and deviance residuals
around zero reflect good fit of the model. In our situation this can be achieved if
δi = 1 and iˆ ≈ 1, which means that the i
th patient with an event was predicted to
be at high risk, or if δi = 0 and iˆ ≈ 0, which means that the i
th patient was
censored and predicted to be at low risk. Those are candidates for non-
responders. 
2. Large values of any residuals are a sign of bad fit of the prognostic model and
here – a possible sign of existing predictive factors. Values of the martingale
residuals close to 1 can be achieved only if δi = 1 and iˆ  ≈  0, i.e. the i
th patient
was predicted to be at low risk but he/she had an event. Such patients are
candidates for negative responders. Their deviance residuals will have values
even larger than those of their martingale residuals (see figure 2). 
3. Large negative values are also sign of a bad fit. Large negative values of the
residuals are achieved if δi = 0 and iˆ  > 0, i.e. the i
th patient was predicted to be
at high risk but he/she was censored (i.e. did better than expected from the
prognostic model). Such patients are candidates for positive responders. A large
negative residual is also possible for patients who had an event and extremely
large predicted hazard rate. Notice, that even though the patient experiences an
event, he/she would still be candidate for a positive responder, since in order to
have such a large hazard rate, he/she must have had a much longer event-free
period than expected. 
The general relationship between size of the predicted hazard and resulting residual
(martingale and deviance) is plotted in figure 2 for censored and uncensored cases,
which is helpful in illustrating the above cases.
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Figure 2: Relationship between the predicted hazard and the martingale and
deviance residuals for the event and censored (always non-positive)
cases. The relationship between predicted hazard and martingale
residual is linear, whereas deviance residuals transform that
relationship.
4.2 The Predictive Model
We suggest the use of a bump hunting model in step 4 of the responder identification
method. Regression trees can be used alternatively as a predictive model.
4.2.1 Regression Trees
We start with the better known regression tree model [9]. As mentioned earlier, the
responder identification idea is based on finding patients in the new treatment group,
who are badly predicted by the prognostic model. We have already shown that
martingale and deviance residuals are suitable for this purpose. Since regression tree
models split the input space into regions, which are described by a part of the input
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variables (the predictive factors), and the size of the output variable in each region is
predicted, we can use regression trees for responder identification. The tree would be
built on the new treatment arm of the data and the residuals to the prognostic model
would be used as an output variable. The hope is that one or more of the final regions of
the tree model would have much larger or much smaller mean of the residuals in them,
than the average for the input space (  0).
We have used the regression tree model as introduced by Breiman et al [9] and as
implemented in S-plus 4.5 for Windows, where the optimal cutpoints are chosen by
minimizing the sum of the averages of the response variable in the resulting regions
over all available splitting variables xj and splitting points ts. 
When using a regression tree instead of a bump model, one should change the responder
identification algorithm as follows: 
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Algorithm 2
Responder Identification with Regression Trees:
Steps 1 through 3 as in algorithm 1 above.
4. Develop a regression tree model on the new treatment group, using the
martingale residuals of the prognostic model as response.
          Note: A tree model describes the whole input space. We are interested only
in extreme regions, i.e. end nodes with patients who have large positive or
large negative residuals. 
5. Order all end nodes by size of the mean response in them.
6. Split the classical treatment group into subgroups as defined by the end
nodes of the regression tree model.
7. Start with the largest in absolute value (by mean of response) negative end
node in the new treatment arm. Compare the survival curves of the new and
classical treatment patients identified with that node. Calculate the p-value of
the log-rank statistic (p(LR)).
8. Add all patients contained in the next largest negative end node (from the list
in 5.) to the previously considered group of new treatment patients. Calculate
p(LR) for the identified groups in the new and classical treatment arms.
9. Repeat step 8 while p(LR) decreases or until there are no more negative end
nodes1.
10. The last combination of end nodes defines the set of positive responders.
The factors involved in defining it are predictive.
11. Repeat steps 7 through 9 for the non-negative end nodes from the list in 5.,
starting with the largest by mean of response.
12. The last combination of non-negative end nodes defines negative
responders. The factors involved in defining it are predictive.
                                                          
1 For data which shows no initial survival difference between the two treatment arms.
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4.2.2 The Bump Hunting Model
Although not originally created for responder identification, bump hunting as proposed
by Friedman & Fisher [10] seems to be tailor made for that purpose. Since this method
is not as well known as regression trees, we will briefly summarize its algorithm. Bump
hunting is a type of greedy optimization algorithm equipped with patience, which
stresses interpretability of the resulting model. It optimizes the average of the output
variable while choosing a series of input variables and corresponding cutpoints in the
following way.
During the model construction process, just as in regression trees, bump hunting looks
for rectangular regions called boxes, but not by minimizing the sum of the averages of
the (two) new regions into which the current space is split. Bump hunting "peels off" a
certain percentage of the data while optimizing the response average of the elements left
in the box. At each peeling step, a variable and a peel-off value is chosen, which
together define a border so that the data points left in the region have the largest mean
of the output variable: Btx yjj ,
max , where B is the box resulting from a peeling at variable
xj and peeling point tj (if a minimal region is sought, one can maximize the negative
average). The top-down-peeling process stops when a minimum number of elements in
the box is reached. Since peeling is a greedy process, the average of the response
variable in the box can often be improved by "pasting" back some of the data to the box.
The bottom-up-pasting process stops when the average in the box can no longer be
improved. In general, when pasting is possible, the new box does have a larger mean of
the response variable, but that rarely has a dramatic effect [10]. Two parameters need to
be specified in the box construction algorithm: peeling quantile α and minimal support
β0. The peeling quantile determines the percentage of data points excluded (peeled
away) from the current box at each peeling step. Friedman and Fisher [10] suggest
values of α between 0.05 and 0.1, which results in the removal of 5% to 10% of the data
at each step. The minimal support is a threshold parameter, which determines the
minimal size of the final box. The choice of the minimal box support involves statistical
and domain of application dependent considerations. The development of a box mean
(i.e. mean of the target variable for data points in the box) with respect to support β can
be observed with the help of the box construction trajectory. The trajectory allows one
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to visually choose an optimal β0. Figure 3 shows an example of a trajectory, constructed
with α = 0.1 where the mean of the response variable is maximized. One can observe
how the mean grows from the mean of the whole data set (0) to about 0.75. The points
on the trajectory represent the consecutively chosen borders. The trade off between
support and mean in the growing box is clearly visible. Notice, maximization is done
only in the direction of mean response. Multivariate optimization which includes both
mean of response and support is not performed in the original bump hunting algorithm.
Figure 3: Trajectory – visualization of the box-building process (α = 0.1).
If the input factors are categorical, that changes the peeling procedure in the following
manner: (i) binary variables allow only one peeling point, which splits the data into two
parts, (ii) variables with more than two categories are treated the same way as in CART:
peeling points are defined in such manner, that any category can be peeled off
regardless of order, (iii) continuous variables are often categorized. In this case, to
preserve the order among categories, we suggest artificially entering the categorized
input variable as "continuous" in the bump hunting algorithm.
  ...           Border 3
Border 2 Border 1
Global Mean
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4.2.3 Stabilized Bump Hunting
Bump models are rather unstable, due to their hierarchical nature. There are two general
ways of assuring that a model is "good": validation and stabilization. Harrell, Lee, &
Mark [11] summarize the procedures for performing external validation and three types
of internal validation: data splitting, cross-validation, and bootstrapping. The external
and the first two internal validation methods require abundance of appropriate data,
which one rarely has. Bootstrapping uses the entire data set in the model building
process and then calculates some goodness-of-fit statistic on a large number of bootstrap
samples taken from the original data.  There is no known goodness-of-fit statistic for the
bump model, therefore, bootstrapping as a validation procedure is not directly
applicable for bump models. The validation choices left are external validation or
internal validation involving data splitting. Both are not always possible.
If there is no direct way to validate a bump model, one should at least reduce the
variability of the bump hunting model resulting from small changes in the data – the so
called stabilizing.  
Bootstrapping can be used as a stabilization procedure during the model building
process (see [12] & [13]). One can use bootstrap samples of the original data in order to
estimate the model coefficients or to choose stronger predictors. Bootstrapping, in all of
its shapes and forms improves or qualifies the predictive capacity of the model.
We stabilize the bump hunting model  in two ways: (i) by categorization of all
continuous predictors and (ii) by bootstrapping at each border selection step.
Categorization of all continuous predictors needs to be done in order to reduce peel-off
point variation. This limits somewhat the power of bump hunting, since it restricts the
peeling process, but it is a necessary preliminary step for the bootstrapped bump
hunting. In order to stabilize the border selection method, we choose each border (i.e.
predictor-restriction combination) after considering all borders chosen from n bootstrap
samples. We fix a border and proceed to the next one only if it was chosen in the
majority of the bootstrap samples.
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Bootstrapping in (ii) is performed according to algorithm 3. Note, that predictor and
border are not equivalent terms. One predictor may appear with different restrictions in
different bootstrap samples. We are only interested in the border frequency as a
combination of predictor and constraint.
Naturally, any stopping criteria which considers only one step at a time is easily
implemented, but in general nearsighted. An alternative is to look several steps ahead
before a stopping decision is made, since a seemingly "bad" border can lead to a "good"
one and result in a better model. We choose not to do this in the following simulation
study in order to fully automate the software implementation and reduce computation
time. 
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Algorithm 3
Stabilized Bump Hunting Algorithm
1. Set the p-value of the log-rank statistic to 1 ( p(LR) = 1) and let T be the set
of all patients in the new treatment arm.
2. Take n bootstrap samples of T and, using the original bump hunting
algorithm, create a trajectory for each one of them, including the original
sample.
3. Consider all n + 1 first borders and the associated predictors and choose the
one which appears most often. If there is a tie, choose the less restrictive
border, i.e. one which results in a box with bigger support when applied to
the original data set.
4. Restrict T using the border from step 3. Calculate the mean response and
the support of the resulting box.
5. Apply the rules restricting T to the classical treatment (or placebo) group and
create a set P of patients under the same restrictions as in T.
6. Calculate the p-value of the log-rank statistic (p(LR)) for the difference in
survival between patients in P and in T. If p(LR) improves2 from its previous
value, return to step 2. If not, stop.
5. Simulation Study
If there were a data set, in which the positive and negative responder groups were
known, one could apply the different versions of the algorithm discussed up to now and
compare their ability to recognize those groups. Unfortunately, this is not possible in a
real life data set, since the actual groups to be identified are not known. 
                                                          
2 The definition of "improves" can be different for different types of data. If initially there is no difference
in survival between the new and the classical treatment groups, the p-value improves when it decreases.
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We simulated a survival type data set to resemble a two arm randomized clinical trial
with a total of 1000 patients, with no difference in survival between the two treatment
groups. A total of seven factors were created: five binomial, one categorical with three
levels, and one continuous in order to test the power of the different procedures in
dealing with different types of variables. The factors (each was a vector of length 1000)
were simulated in the following way. Each value of the binary factors X1, X4, X5, X6,
and TREAT was chosen at random from a binomial distribution with probability p = .5.
TREAT = 0 denotes placebo patients, TREAT = 1 denotes new treatment patients. The
categorical factor X2 values were chosen at random from the set {0, 1, 2} with
corresponding probabilities {.33, .33, .34}. The continuous factor X3 had valued
chosen at random from a normal distribution with mean five and variance two. Follow-
up time for this model was simulated to be Weibull distributed with shape parameter
equal to two and scale parameter equal to the relative hazard, i.e. TIME was created to
be a vector of length 1000, each component of which was chosen at random from the
unique to each patient Weibull distribution, depending on his/her relative hazard. We
used the following Cox-PH model with prognostic and predictive parts for defining the
hazard:
predictiveprognosticetXt  )()|( 0
,522654
3311
maxmin
321
TREATXXcTREATXXXcpredictive
XXXXprognostic

 
where cmin and cmax are coefficients in the predictive part, 1, 2, and 3 are coefficients
in the prognostic part, and X22 indicates X2 = 2.
The prognostic coefficient values 1 = ln3, 2 = -(ln3)/5, and 3 = (ln3)/10 ( 1.0986,
-.2197, and .1099 respectively) simulate an interaction between categorical factor X1
and continuous factor X3. The interaction is to be interpreted as follows: in absence of
factor X1 (X1 = 0), increase of factor X3 from 0 to 10 increases the relative hazard from
1 to 3; in presence of factor X1 (X1 = 1), increase of factor X3 from 0 to 10 decreases
the relative hazard from 3 to 1.
Kehl & Ulm
Responder Identification in Clinical Trials with Censored Data 19
The following pairs of values for cmin and cmax were chosen for further investigation: (-2,
2), (-1, 1), and (-.5, .25). Note, that larger absolute values of the coefficients simulate
stronger influence of the predictive part of the model on hazard. In addition, since cmin is
always negative, it decreases hazard, i.e. patients with X4 = 1 & X5 = 1 & X6 = 1
would have lower hazard under treatment than under placebo – this is the simulated
positive responder group. Conversely, since cmax is always positive, it increases
hazard, i.e., patients with X2 = 2 & X5 = 1 would have higher hazard under treatment
than under placebo – this is the simulated negative responder group.
Censoring was assigned at random and is independent of time.  Three different
percentages of censoring were considered: 10%, 30%, and 70%.
The above described survival data was simulated in 9 groups with different model
coefficients and censoring rates as shown in table 1. The survival curves of the placebo
(TREAT = 0) and treatment (TREAT = 1) groups were compared in each simulation
group. The overall survival difference between the two treatment arms was not
significant at the .05 level in each of the 9 groups, as it was expected by the simulation
study design. The simulated responder groups, however, differ in survival between the
treatment and placebo groups (as expected).
Table 1: Simulation groups
Simulation 
group #
cmin cmax % censored
1 -2 2 10
2 -1 1 10
3 -.5 .25 10
4 -2 2 30
5 -1 1 30
6 -.5 .25 30
7 -2 2 70
8 -1 1 70
9 -.5 .25 70
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5.1 The Cox-PH model with treatment interaction term
Simulation groups 1, 5, & 9 were chosen as representative in an attempt to evaluate the
power of the most frequently used variable selection process, forward stepwise
selection, to identify the simulated Cox-PH model with interactions as "best." Forward
selection with likelihood ratio test as model improvement criteria was used with
inclusion p(Wald) = .01 and exclusion p(Wald) = .05. Table 2 gives a summary of this
investigation. Simulation group 1 has strong simulated treatment effect (easy to detect)
and only 10% censoring. Simulation group 5 has medium strength simulated treatment
effect and 30% censoring. Simulation group 9 has 70% censoring and slight treatment
effect (difficult to detect). A total of 10 data sets were simulated in each group. The null
model (no factors) and the correct model likelihood ratios were computed on each data
set. Forward stepwise selection was applied on each data set four times: once including
all factors X1 through X6 and TREAT and all their possible two-way interactions (a
total of 28 terms to choose from), once including all single factors and all their up to
third order interactions (63 terms), all single factors and all their up to fourth order
interactions (98 terms), and finally, all single factors and their up to fifth order
interactions (119 terms). The largest interaction term in the correct model is of fourth
order. Interactions of up to fifth order were considered in order to check if forward
selection including interaction terms of higher than needed order would choose more
complicated terms than necessary. This should give a hint on the behavior of the
automated selection procedure in a "real life" data set, for which the correct model is
unknown.
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Table 2: Table of likelihood ratios for the null model, the models found with forward
selection when different highest order interactions were present, and the
correct model.
Simulation
group
Run Null (df=0) 2d order
interaction
(df)
3d order
interaction
(df)
4th order
interaction
(df)
5th order
interaction
(df)
Correct
(df=6)
1 11239 11076 (11) 10976 (8) 10942 (6) 10942 (6) 10942
2 11110 10941 (9) 10860 (5) 10844 (4) 10844 (4) 10820
3 11121 10986 (10) 10884 (9) 10860 (5) 10860 (5) 10814
4 11161 10946 (9) 10893 (6) 10868 (4) 10857 (6) 10822
5 11094 10966 (9) 10787 (11) 10803 (5) 10803 (5) 10764
6 11093 10929 (10) 10861 (5) 10819 (5) 10804 (8) 10784
7 11132 10914 (13) 10801 (12) 10736 (10) 10736 (10) 10761
8 11103 10919 (11) 10857 (5) 10819 (5) 10819 (5) 10803
9 11109 10998 (6) 10878 (7) 10828 (7) 10828 (7) 10805
1
10 11189 11015 (11) 10912 (12) 10894 (8) 10894 (8) 10903
1 8651 8608 (3) 8593 (5) 8581 (5) 8581 (5) 8555
2 8705 8677 (3) 8633 (6) 8636 (5) 8636 (5) 8632
3 8441 8422 (2) 8394 (5) 8395 (3) 8382 (5) 8366
4 8525 8491 (5) 8476 (3) 8472 (3) 8472 (3) 8447
5 8407 8381 (3) 8321 (9) 8329 (7) 8329 (7) 8324
6 8412 8387 (3) 8365 (5) 8363 (4) 8363 (4) 8343
7 8444 8410 (3) 8401 (3) 8384 (4) 8384 (4) 8368
8 8584 8529 (4) 8522 (3) 8503 (3) 8503 (3) 8472
9 8428 8397 (3) 8342 (4) 8335 (4) 8335 (4) 8316
5
10 8586 8547 (3) 8495 (3) 8486 (3) 8486 (3) 8453
1 2740 2722 (3) 2722 (3) 2722 (3) 2724
2 2474 2455
3 2614 2600
4 2643 2627 (2) 2627 (2) 2627 (2) 2631
5 2845 2829 (3) 2829 (3) 2829 (3) 2829 (3) 2823
6 2956 2945
7 2509 2489
8 2738 2729 (1) 2729 (1) 2729 (1) 2729 (1) 2724
9 2751 2745
9
10 2291 2279
bold = models with better LR than the corresponding correct model
             = identical models (valid for the row)
5.2 The proposed responder identification method
The three versions of the responder identification method were applied on 200 data sets
in each of the nine simulation groups from table 1. Martingale residuals were calculated
on half of the data sets in each group. Deviance residuals were calculated on the other
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half. Our goals were: (1) to evaluate the prognostic power of the responder
identification procedure with regression trees, ordinary and stabilized bump hunting, by
comparing the identified through the method groups of responders to the correct groups
and (2) to compare the power of identification of the method when martingale and
deviance residuals are used as response variables in the predictive models. Step 1 of the
responder identification algorithm can be skipped in the simulation study. The
prognostic model here is known. It was simulated to contain factors X1, X3, and their
linear interaction.  Table 3 shows the average number of times the entire responder sets
were chosen correctly over the 100 data sets in each simulation group, each residual
type, and each predictive model. 
Table 3: Number of times the correct responder groups were chosen from 100
simulations for each simulation group, using martingale (MART) or
deviance (DEVI) residuals as response in a regression tree (tree), bump
hunting (original), or stabilized bump hunting (stabilized) predictive
model. MIN denotes search for a minimal region in the residuals (i.e.
positive responders); MAX – maximal region (i.e. negative responders).
MART DEVI
tree original stabilized tree original stabilized
sim.
group #
MIN MAX MIN MAX MIN MAX MIN MAX MIN MAX MIN MAX
1 98 0 71 95 97 99 100 65 42 100 72 100
2 73 23 65 98 88 100 94 71 33 100 52 100
3 22 10 47 94 84 99 52 10 26 100 46 100
4 94 0 72 98 99 99 94 81 39 100 78 100
5 76 41 67 97 92 99 76 70 35 99 59 100
6 28 6 52 97 79 100 33 6 22 100 36 100
7 66 60 75 96 97 99 59 52 43 100 78 100
8 51 53 67 94 89 99 53 32 31 100 48 100
9 21 4 56 94 83 98 10 1 26 99 35 100
It turned out, that in the simulated data the p-value of the log-rank statistic never grew
insignificant in the stabilized and original bump hunting. We developed the bump
hunting models using minimal support of .05 as stopping criteria. Since we knew the
correct responder and non-responder groups, we considered just one box per bump and
just the first three selected borders. The developed model was considered correct if the
first three borders of the maximal box were any permutation of the following: X2  0,
X2  1, X5  0 and the minimal box – any permutation of the following borders: X4  0,
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X5  0, X6  0. Naturally, the correct bumps are usually not known. One does not even
know how many boxes each bump has. Fortunately, "real life" data sets are not as clean
and ordered as our simulated data, so that the bump growth process can actually be
governed by the log-rank statistic, as in the suggested algorithm (see [2]).  
5.3 Results
5.3.1 Cox-PH model with treatment interaction
In defense of the forward stepwise selection procedure, one should note, that in most
cases (21 out of 24 constructed models) it did not add a fifth order interaction term, but
delivered the model chosen from the procedure including up to fourth order interactions
(see table 2). Unfortunately, it also chose the correct model only once out of 30 times
(run 1, simulation group 1)!
Consider first simulation group 9, the most realistic one. In 6 out of 10 cases the
forward selection procedure did not find any significant factors. In the 4 data sets, in
which significant factors were found, they were other than the simulated ones (i.e.
noise). In simulation groups 1 and 5 (see table 2), the likelihood ratio of the correct
model was better than that of the forward selected models for 18 out of 20 data sets. In
the cases where LR(forward) < LR(correct) the forward selected model contained the
correct model and some additional factors. The overall impression is that the Cox-PH
model with interactions is not a sensitive enough method for responder identification
purposes when the effect of factors and factor combinations on treatment is weak and
there is large percentage of censoring in the data. It performs well on data sets with
small to moderate percent censoring and strong to moderate treatment effect. The
problem with applying this responder identification procedure in praxis is that the
correct model is unknown and the forward selection procedure has low power when
choosing from a large number of terms.
5.3.2 Algorithm 2 with a regression tree predictive model
Deviance residuals in general performed about the same or better than martingale
residuals in positive responder identification (i.e. negative nodes). The same was true
for negative responders (positive nodes), except for data sets with large percentage of
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censoring. Overall, the responder identification algorithm using regression trees showed
acceptable power of identification for data, in which the groups to be identified were
with much larger (or much smaller) hazard than the entire data set (sim. groups 1, 4, & 7
with large predictive coefficients). The results were miserable for the data in sim.
groups 3, 6, & 9, where the predictive coefficients were very small. This leads us to the
conclusion, that regression trees are not sensitive enough to be applied in responder
identification. Nevertheless, if we had to make a recommendation which residuals
to be used as a response factor in CART, we would prefer deviance residuals, as
they have acceptable performance at least for the case when censoring is not too
large and the responder coefficients are strong (sim. groups 1, 2, 4, & 5). For data
with large percentage censoring it is preferable to use martingale residuals. 
5.3.3 Algorithms 1 & 3 with bump hunting predictive models
The results with bump hunting seem to be independent of percent censoring: simulation
groups (1, 4, 7), (2, 5, 8), and (3, 6, 9) have similar outcomes across the different
methods. Size of the cmin and cmax coefficients show effect: larger in absolute value
coefficients result in better performance of the different methods. Martingale residuals
show to be better suited for positive responder identification (minimal bump) than
deviance residuals. For negative responder identification (maximal bump) deviance
residuals perform just as well or slightly better than martingale residuals. In all cases
where improvement was possible, the stabilized bump hunting algorithm showed much
better results than the original algorithm.
Deviance residuals perform excellent in negative responder identification and
unsatisfactory in positive responder identification. Their use is not recommended when
both responder groups are needed. The stabilized bump hunting procedure with
martingale residuals as response variable delivers excellent results both in positive
and negative responder identification, especially if the effect is strong.
5.4 Comparison
We did not formally include the classical Cox-PH model with treatment interactions in
this comparison, because simulations with this model were performed only on groups 1,
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5, & 9 and only on 10 data sets in each group. The correct model was found on only one
data set in the “easiest” simulation group 1. This results in 10%, 0%, & 0% recognition
rate for groups 1, 5, & 9 respectively. Then the Cox-PH model with treatment
interactions is only better than the regression tree and mantingale residuals version of
the responder identification algorithm. 
Figure 4 gives a summary of the results of the responder identification algorithm when
the regression trees, original, and stabilized bump hunting is employed (see table 3).
Note, that comparison between a tree and a bump model can only be made in a very lose
sense, since tree models describe the entire space and bump models – just extreme parts
of it. In 16 out of the 18 cases with martingale residuals as response, bump hunting was
more powerful than regression tree as predictive model in the responder identification
algorithm. In the two other cases the results of both models were comparable; regression
tree performed slightly better than bump hunting. When deviance residuals were used as
a response variable, all three versions of the responder identification method performed
unsatisfactory in finding positive responders, especially on data sets with high
percentage of censoring. Finding negative responders with deviance residuals and bump
hunting (both original and stabilized) was extremely successful. Regression trees
performed unsatisfactory in a combination with deviance residuals in the responder
identification method when negative responders were sought.  It is, therefore,
recommendable that the responder identification method be used with martingale
residuals as a response variable in the stabilized bump hunting. 
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Figure 4: Number of correctly identified responder groups from 100
simulations in each simulation group.
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5.5 Implementation
This simulation study was performed with the help of the readily available statistical
packages SPSS and S-PLUS and the programming languages S and C. The Cox model
with interactions and the Kaplan-Meier curves were generated using the survival
analysis tools in SPSS 10.0. The simulation of all data sets, as well as the bump hunting
analysis were done with especially written for the purpose S programs, which run with
S-PLUS 4.5. Construction of the bump models was done in S-PLUS for Unix, using the
algorithms of Becker [14] called .boxes, .express.boxes, and .border.ranking, which use
C subroutines.  The part of the simulation study involving regression tree models was
done in S-PLUS for Windows. S routines using the S-PLUS tools for regression tree
construction were written for that purpose. 
6. Discussion
The responder identification method was developed with a situation in mind, in which
overall the new treatment does not show to be better or worse than the classical
treatment (i.e. the survival curves in both treatment arms do not differ significantly).
The method needs slight alteration if initial difference in survival is present. Ordinarily,
one would use the change in p-value of the log-rank statistic as a stopping criteria in the
bump hunting procedure (Algorithm 3, point 6). In the peeling process of bump hunting,
one would reduce the new treatment patient arm step by step. If there is a significant
difference for the entire population, reducing the group would lead to less and less
significant p-values before it eventually reduces the new treatment group to this one
special subgroup, for which the p-values become significant again to show difference in
survival between the new and the old treatment subgroups in the opposite direction from
the initial situation. In those cases, the p-value of the log-rank statistic cannot be used as
an automatic stopping criteria and the growth of the bump hunting model needs to be
controlled manually. Alternatively, the algorithm can be changed to "intelligently"
evaluate the p-values by looking some steps ahead.
As further improvement to the responder identification method for censored data, one
may choose to allow for pasting in the bump model growth or looking several steps
ahead at the log-rank statistic performance in the predictive model growth. As discussed
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earlier, this improves the shortsightedness of a stopping criteria, but unfortunately also
complicates the automation of algorithms. 
The best version of the responder identification algorithm (algorithm 3) can be modified
to include pasting as well. In this case, we would use the minimal support (calculated in
the original data set) as stopping criteria of the peeling process instead of the p-value of
the log rank statistic. Pasting borders would also be chosen through bootstrapping. Here
we can use both the p-value of the log rank statistic and the indicator for increase
(decrease) of the box mean as stopping parameter.
We limit the stabilized bump hunting procedure to categorical or categorized continuous
factors, but we are currently working on changes allowing continuous factors as well.
So far we have only considered the ordinary Cox-PH model as a prognostic model in
our algorithms. One may choose to investigate time-varying effects of the prognostic
factors before looking for predictive factors. Additional research is needed on the
influence the choice of prognostic model exerts on the predictive model outcome.   
A note on application: We are currently using the best version of the proposed
responder identification method as a routine on all appropriate clinical data we have.
First results can be seen in [2].
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